Meloxicam Tablet
Product Images NDC 71610-881

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 71610-881). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0881 30)

Meloxicam USP 7.5 mg tablet label shows packaging information for 30 tablets. The label includes NDC 71610-881-30 and storage instructions to keep between 20-25 degrees Celsius. It is manufactured by PD-RPH Pharmaceuticals and labeled by Aphena Pharma Solutions - Tennessee, LLC. The package is for oral use and prescription only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Mg1 (Mg1)

A text panel containing safety instructions and warnings related to the use of NSAIDs. It advises against taking NSAIDs right before or after coronary artery bypass graft surgery and cautions about increased heart attack risk if NSAIDs are taken after a recent heart attack. The text is in English and formatted with bold and regular font for emphasis.*

FDA Label Image

Mg2 (Mg2)

A text panel discussing the increased risk factors for getting an ulcer or bleeding when using NSAIDs, listing conditions and medications such as corticosteroids, anticoagulants, SSRIs, and SNRIs. It includes risk factors like age, health status, smoking, alcohol consumption, and medical history related to stomach or liver disease.*

FDA Label Image

Mg3 (Mg3)

A partial text panel displaying dosing instructions emphasizing use exactly as prescribed, at the lowest dose possible, and for the shortest time needed. The visible content is related to usage guidance for a medication, without specifying the drug name or details.*

FDA Label Image

Mg4 (Mg4)

A Drug Facts panel listing potential serious side effects and symptoms requiring immediate medical attention for MELOXICAM 7.5 mg tablets. The text includes symptoms like chest pain, slurred speech, swelling of the face or throat, and weakness on one side of the body, among others.*

FDA Label Image

Mg5 (Mg5)

This image shows a text panel listing potential side effects associated with the drug Meloxicam. The side effects include symptoms like nausea, fatigue, diarrhea, itching, yellowing of skin or eyes, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movements, unusual weight gain, skin rash, and swelling of limbs.*

FDA Label Image

Structural (Structural Formula)

Chemical structure diagram of meloxicam, showing the arrangement of atoms and bonds in the molecule. The image includes a benzene ring, sulfonamide group, and other characteristic chemical features consistent with the meloxicam compound.*

FDA Label Image

Table 1a (Table 1a)

A table showing adverse event percentages occurring in 2% or more of patients taking Meloxicam 7.5 mg daily compared to placebo, Meloxicam 15 mg daily, and Diclofenac 100 mg daily during a 12-week osteoarthritis clinical trial. The table categorizes events by system organ class, including gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin.*

FDA Label Image

Table 1b (Table 1b)

Data table summarizing adverse events occurring in 2% or more of patients treated with Meloxicam compared to placebo in two 12-week rheumatoid arthritis placebo-controlled trials. It lists patient numbers and percentages of various disorders such as gastrointestinal, general disorders, infections, musculoskeletal, nervous system, and skin reactions related to Meloxicam 7.5 mg daily, 15 mg daily, and placebo groups.*

FDA Label Image

Table 2.1 (Table 2.1)

Data table listing adverse reactions of Meloxicam organized by body systems, including cardiovascular, central and peripheral nervous system, gastrointestinal, hepatic, metabolic, psychiatric, respiratory, skin, special senses, and urinary system effects.*

FDA Label Image

Table 2 (Table 2)

Table displaying adverse events occurring in 2% or more of patients treated with Meloxicam 7.5 mg or 15 mg daily in 4 to 6 weeks and 6 month active-controlled osteoarthritis trials. It categorizes events by system (gastrointestinal, body as a whole, central and peripheral nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, urinary) with percentages for each dose and trial duration.*

FDA Label Image

Table 3.1 (Table 3.1)

A drug information text panel detailing clinical impact and intervention instructions for drug interactions of meloxicam with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed. It highlights risks such as elevated lithium levels, methotrexate toxicity, cyclosporine nephrotoxicity, increased GI toxicity, and myelosuppression, along with monitoring and dosing recommendations during concomitant use.*

FDA Label Image

Table 3 (Table 3)

Table titled 'Clinically Significant Drug Interactions with Meloxicam' detailing clinical impacts and intervention guidelines for drugs that interfere with hemostasis, aspirin, ACE inhibitors, angiotensin receptor blockers or beta-blockers, and diuretics when used concomitantly with meloxicam.*

FDA Label Image

Image Description (Table 4)

A data table presenting single dose and steady-state pharmacokinetic parameters for oral 7.5 mg and 15 mg Meloxicam tablets and capsules. Parameters include Cmax, tmax, t1/2, CL/f, and Vz/f measured in healthy adults, elderly males and females, and patients with renal failure or hepatic insufficiency under fasted conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.